Insider Trading Activity Foundation Medicine Inc (NASDAQ:FMI) – COO Sold 4,405 shares of Stock

19

Insider Trading Activity For Foundation Medicine Inc (NASDAQ:FMI)

Steven J Kafka , COO of Foundation Medicine Inc (NASDAQ:FMI) reportedly Sold 4,405 shares of the company’s stock at an average price of 34.55 for a total transaction amount of $152,192.75 SEC Form

Insider Trading History For Foundation Medicine Inc (NASDAQ:FMI)

  • On 4/16/2014 Vincent Miller, Insider, sold 30,000 with an average share price of $26.86 per share and the total transaction amounting to $805,800.00. View SEC Filing
  • On 4/16/2014 Jason Ryan, SVP, sold 3,541 with an average share price of $26.36 per share and the total transaction amounting to $93,340.76. View SEC Filing
  • On 5/6/2014 Vincent Miller, Insider, sold 3,000 with an average share price of $30.00 per share and the total transaction amounting to $90,000.00. View SEC Filing
  • On 6/5/2014 Steven J Kafka, COO, sold 4,500 with an average share price of $24.19 per share and the total transaction amounting to $108,855.00. View SEC Filing
  • On 6/5/2014 Jason Ryan, SVP, sold 10,000 with an average share price of $24.06 per share and the total transaction amounting to $240,600.00. View SEC Filing
  • On 6/13/2014 Krishna Yeshwant, Director, sold 1,300,000 with an average share price of $22.40 per share and the total transaction amounting to $29,120,000.00. View SEC Filing
  • On 6/16/2014 Jason Ryan, SVP, sold 2,361 with an average share price of $22.61 per share and the total transaction amounting to $53,382.21. View SEC Filing
  • Analyst Ratings For Foundation Medicine Inc (NASDAQ:FMI)
    These are 5 Hold Ratings, 1 Buy Rating .
    The current consensus rating for Foundation Medicine Inc (NASDAQ:FMI) is Hold (Score: 2.17) with a consensus target price of $28.00 , a potential (13.31% downside)

    Analyst Ratings History For Foundation Medicine Inc (NASDAQ:FMI)

    • On 7/30/2015 JMP Securities Downgraded rating Outperform to Market Perform
    • On 9/16/2015 Wells Fargo & Co Downgraded rating Outperform to Market Perform
    • On 11/4/2015 Wedbush Lower Price Target of rating Neutral with a price target of $26.00 to $19.00
    • On 2/26/2016 Goldman Sachs Group Inc Lower Price Target of rating Neutral with a price target of $17.00 to $15.00
    • On 5/4/2016 Leerink Swann Reiterated Rating Hold
    • On 8/3/2016 JPMorgan Chase & Co. Reiterated Rating Hold with a price target of $25.00
    • On 8/4/2016 BTIG Research Reiterated Rating Hold

    About Foundation Medicine Inc (NASDAQ:FMI)
    Foundation Medicine, Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. The Company’s segment is the business of delivering molecular information about cancer to its customers. Its products provide genomic information about each patient’s individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. Its flagship clinical molecular information products, FoundationOne for solid tumors, and FoundationOne Heme for blood-based cancers or hematologic malignancies, including leukemia, lymphoma, myeloma and advanced sarcomas, are genomic profiles designed for use in the routine care of patients with cancer. Its other products include FoundationACT (Assay for Circulating Tumor deoxyribonucleic acid (DNA)), GeneKit, FoundationCORE, FoundationICE and the SmartTrials program.

    Recent Trading Activity for Foundation Medicine Inc (NASDAQ:FMI)
    Shares of Foundation Medicine Inc closed the previous trading session at 32.30 0.00 0.00% with 132,461 shares trading hands.